The binding of an antibiotic to proteins or to other macromolecules in body fluids can reduce its effective concentration, decrease its antibacterial activity and modify its pharmacokinetics or toxicity (16, 19, 24) . Most studies designed to measure protein binding of aminoglycosides by direct methods have shown little or no binding of these antibiotics to serum proteins (3, 10, 23) , but significant protein binding of neomycin has been reported (25) . The observation that renal clearances of aminoglycosides are similar to the glomerular filtration rate in man also suggest that protein binding of aminoglycosides is not physiologically important (11) . During a reinvestigation of the binding of gentamicin to serum proteins, we observed significant protein binding of gentamicin by equilibrium dialysis (C. H. Ramirez-Ronda, R. K. Holmes, and J. P. Sanford., J. Clin. Invest. 53:63a, abstr. 236, 1974) . In further studies to reconcile these results with the published observations cited abqve, we have found that the concentrations of divalent cations, especially magnesium, are critically important in determining whether or not the aminoglycosides bind to serum proteins. Our initial experiments, as well as the study showing significant protein binding of neomycin cited above, were performed in the absence of divalent cations. In contrast, at the concentrations of magnesium and calcium present in serum or extracellular fluid, binding of aminoglycosides to serum proteins is minimal.
In earlier studies, concentrations of divalent cations were also shown to affect the susceptibility to gentamicin of some gram-negative bacteria (8, 9, 28) . For example, in Pseudomonas aeruginosa but not in Escherichia coli, resistance to gentamicin is enhanced by high concentrations of magnesium or calcium in the medium used for susceptibility testing (9) . Taken together, the effects of divalent cations on bacterial susceptibility to gentamicin and on the binding of aminoglycosides to serum proteins led us to test the hypothesis that the enhanced in vitro resistance of P. aeruginosa to gentamicin in (20) . The specific activity of the purified 3H-labeled gentamicin was 0.8 Ci/mg (20a) . The 'H-labeled gentamicin was diluted with nonradioactive gentamicin to give lower specific activities as required for experiments described in the text. Concentrations of all aminoglycosides are expressed as ug of free base per ml.
Tris(hydroxymethyl)aminomethane (Tris) was from Sigma (St. Louis, Mo.). All other chemicals were reagent grade and were purchased commercially.
Assays for aminoglycoside antibiotics. Three types of methods were used to measure the concentrations of aminoglycoside antibiotics in this study: (i) enzymatic assay with gentamicin adenylyltransferase (13) or kanamycin acetyltransferase (12) ; (ii) microbiological assay with Bacillus subtilis ATCC 6633 as the indicator strain (1); and (iii) measurement of radioactivity in 'H-labeled gentamicin by liquid scintillation spectrometry. Observed counts were corrected by use of internal standards for differences in quenching of tritium in buffer, in serum, and in serum ultrafiltrate.
Serum. Pooled human serum was prepared from clotted whole blood obtained from healthy volunteers who had not recently received antimicrobial agents or other drugs. An ultrafiltrate of pooled human serum was prepared by using a PM-10 membrane filter (Amicon Corp., Lexington, Mass.). Serum and serum ultrafiltrate were sterilized by passage through membrane filters with 0.45-pm average pore diameter (Millipore Corp., Bedford, Mass.) and were stored at 4 C. The concentration of calcium in the pooled serum was 2.33 mM and in the serum ultrafiltrate was 1.57 mM. The concentration of magnesium in the pooled serum was 0.71 mM and in the ultrafiltrate was 0.51 mM.
Measurements of binding of aminoglycoside antibiotics to human serum. Our procedure for equilibrium dialysis was based on the method of Klotz (17) as modified by Kunin (18) . In most experiments, 1-ml samples of pooled human serum were placed in sections of no. 8 (3/8-inch diameter) dialysis tubing (Union Carbide Co., Chicago, Ill.) tied at both ends, and the specimens were suspended in 15-ml volumes of buffer (0.05 M Tris-Cl, pH 7.4, containing 0.15 M NaCl plus calcium and magnesium at concentrations as indicated) in test tubes (20 by 150 mm) with screw caps. In some experiments, the Tris buffer was replaced with 15 ml of serum ultrafiltrate previously adjusted to a pH of 7.4 to 7.5 with CO, or with 15 ml of 0.05 M potassium phosphate buffer at pH 7.4. Aminoglycoside antibiotics were usually added to the buffer but in some experiments were added to the serum specimens, and dialysis was carried out at 37 C for 48 h with the tubes agitated in a rotating drum (Model TC-7, New Brunswick Scientific Co., New Brunswick, N.J.). Control experiments documented that equilibrium was achieved in this period of time. Volumes of serum and buffer were recorded at the completion of dialysis, and samples of each were stored at 4 C until assays for aminoglycosides were performed. The volumes of the serum specimens after dialysis were usually between 1.3 ml and 1.6 ml. If the concentration of an aminoglycoside in serum is designated At (total aminoglycoside concentration) and the concentration in buffer is designated Af (free aminoglycoside concentration), then the concentration of bound aminoglycoside Ab is equal to (At -A,). 
Binding to serum proteins in the absence of divalent cations is a general property of aminoglycoside antibiotics and was observed with all aminoglycosides tested ( Table 2 ). These data are representative of results obtained with each aminoglycoside tested at several concentrations comparable to the range of blood levels that can be achieved in man during therapy with these drugs. To eliminate the possibility that the observed binding could reflect an artifact of the equilibrium dialysis method, the binding of gentamicin to serum proteins in Tris-Cl buffer without divalent cations was confirmed by gel filtration experiments (Fig. IA) . In addition, experiments with 3H-labeled gentamicin were performed both by equilibrium dialysis (data not shown) and by gel filtration (Fig. 1B) to rule out the possibility that apparent binding might (12, 13) .
The initial concentrations of antibiotics in the dialysis buffers were approximately 1 g/ml for gentamicin, gentamicins Cl, Cla, and C2, tobramycin, and sisomicin, and 7 ,g/ml for kanamycin and amikacin. Table 3 . On a molar basis, Mg2+ is much more effective than Ca2+ in interfering with the binding of gentamicin to serum. At physiological concentrations of Mg2+ (1.0 mM) and Ca2t (2.5 mM) binding of gentamicin to serum proteins is completely inhibited.
Measurements of binding of gentamicin to serum proteins by the vacuum ultrafiltration method of Bennett and Kirby (2) support the conclusion that gentamicin does not bind significantly to human serum under normal physiological conditions (Table 4 ). In these experiments, assays of gentamicin were performed by all three methods described above with concordant results.
Binding of aminoglycosides to bacteria. After addition of 3H-labeled gentamicin to cultures of P. aeruginosa in minimal medium, binding of gentamicin to the bacteria occurs rapidly. Maximal binding is observed within minutes, but binding is strongly inhibited by divalent cations (Fig. 2) . In cultures of P. aeruginosa containing 5 ig of 3H-labeled gentamicin per ml but lacking divalent cations, up to 30% of the gentamicin is bound within 2 min. As the concentration of Mg2+ increases from 0 mM to 1.0 mM, binding of 3H-labeled gentamicin to 10 Concentrations of gentamicin (0) were determined by enzymatic assay (A) or by measurement of radioactivity in 3H-labeled gentamicin (B). The large peak in the absorbance profile at 280 nm (-) represents serum proteins excluded by Sephadex G-25 that appear at the void volume of the column. Protein binding of gentamicin is responsible for increased concentrations of gentamicin coincident with the protein peak and reduced concentrations of gentamicin in the fractions eluting after the protein peak. The data in (A) and (B) are from separate experiments by using the same column of Sephadex G-25.
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on November 3, 2017 by guest http://aac.asm.org/ Downloaded from P. aeruginosa decreases about 10-fold. Similar but less striking inhibition of the binding to gentamicin to P. aeruginosa is observed in the presence of Ca2t.
Binding of 3H-labeled gentamicin was mea- (8, 9, 28) . Gilbert and associates found that the average minimal inhibitory concentration of' gentamicin for P. aeruginosa increased from 1.8 mg/ml to 5.6 gg/ml as the magnesium concentration increased from 0.12 mM to 1.9 mM in the presence of' 0.17 mM calcium. Zimelis and Jackson studied the bactericidal effects of gentamicin on P. aeruginosa and found that the addition of' calcium permitted growth of P. aeruginosa in the presence of' an otherwise lethal concentration of the drug (28) . The effects of' divalent cations on the actions of gentamicin have not been seen in E. coli and Klebsiella pneumoniae. Our data confirm previous observations that divalent cations can increase the phenotypic resistance of P. aeruginosa but not of E. coli to gentamicin. In addition, we have shown that the enhanced resistance of P. aeruginosa in the presence of Ca2`or Mg2+ is associated with decreased uptake of gentamicin by the bacteria. Although this decreased uptake provides a reasonable explanation for the enhanced resistance of P. aeruginosa to gentamicin in the presence of divalent cations, the mechanisms for inhibition of' uptake by divalent cations remain to be established.
Our data show that maximal binding of gentamicin to P. aeruginosa occurs very rapidly and suggest that the initial binding is most likely to the cell wall. It is therefore possible that antagonism of the activity of aminoglycosides by divalent cations is due to effects of these cations on the bacterial cell wall. The cell wall of P. aeruginosa contains calcium, magnesium, and other cations that appear to link polysaccharide subunits and contribute to the structural integrity of the cell wall (5, 6, 7). When P. aeruginosa is exposed to EDTA, polysaccharide is released from cell wall and susceptibility of the bacteria to several antibiotics including penicillin and ampicillin increases (27) . The influence of EDTA on susceptibility of P. aeruginosa to penicillins can be reversed by addition of' calcium and magnesium, and this enhanced susceptibility of EDTA-treated cells is seen with P. aeruginosa but not with E. coli (4, 22) . These similarities in the effects of EDTA and of' divalent cations on the susceptibility of' P. aeruginosa to penicillins and to aminoglycosides suggest that disruption of cell wall integrity in the absence ot' divalent cations may increase the accessibility of the cellular targets to these antibiotics. Although little data have been published concerning the mechanisms for uptake and internalization of aminoglycosides by P. aeruginosa, Bryan and his colleagues have recently undertaken a detailed investigation of this problem (L. E. Bryan, M. S. Shahrabadi, and H. M. Van Den Elzen., Prog. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., 14th, San Francisco, Calif., Abstr. 166, 1974) .
Although binding of' aminoglycosides to serum proteins does not appear to be pharmacologically important in normal man, our data show clearly that signif'icant protein binding of aminoglycosides can occur under appropriate conditions in vitro. With some aminoglycosides such as gentamicin, the pharmacokinetic responses of individual patients to standard dosage regimens are notoriously unpredictable (15, 23, 26) . The possibility that significant binding of aminoglycosides to serum or to tissue proteins might occur under pathological conditions in man and might help to determine variations in the pharmacokinetics or in the antibacterial effectiveness of gentamicin in individual patients should therefore be considered and deserves investigation in appropriate clinical situations. ACKNOWLEDGMENTS This study was supported by training grant 5 T01 AI 00030 and by research grant 5 R01 AI 10388 from the National Institute of Allergy and Infectious Diseases.
